BioLineRX announces annual shareholder meeting

• BioLineRX will hold its annual general meeting of shareholders on Sept. 23, 2026.
• Shareholders will vote on the re-election of three Class III directors to terms running to the 2029 annual meeting.
• Other items include an increase in authorized share capital with a related amendment to the articles of association.
• Equity-based compensation grants are also up for approval, including awards for CEO Philip Serlin and option grants for certain directors.
• The meeting will also consider reappointing Kesselman & Kesselman (PwC member firm) as independent auditor for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004184), on August 18, 2026, and is solely responsible for the information contained therein.